Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
520 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05201781 | A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel | recruiting | Phase 4 | 295 | Janssen Research & Development, LLCINDUSTRY | 8 | Sep 25, 2026 | clinicaltrials |
| NCT07839988 | De-escalation Strategy of Tyrosine Kinase Inhibitors Before Treatment Discontinuation in Patients With Chronic Myeloid Leukemia(DESCML) | not yet recruiting | Phase 4 | 280 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 |
| Sep 24, 2026 |
| clinicaltrials |
| NCT03340506 | Dabrafenib and/or Trametinib Rollover Study | recruiting | Phase 4 | 100 | Novartis PharmaceuticalsINDUSTRY | 14 | Sep 23, 2026 | clinicaltrials |
| NCT05144997 | Lorlatinib Continuation Study | active not recruiting | Phase 4 | 76 | PfizerINDUSTRY | 8 | Sep 23, 2026 | clinicaltrials |
| NCT07218341 | A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | recruiting | Phase 4 | 150 | Eli Lilly and CompanyINDUSTRY | 17 | Sep 22, 2026 | clinicaltrials |
| NCT05161195 | Roll-over Study to Allow Continued Access to Ribociclib | active not recruiting | Phase 4 | 134 | Novartis PharmaceuticalsINDUSTRY | 22 | Sep 18, 2026 | clinicaltrials |
| NCT02584933 | Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study | active not recruiting | Phase 4 | 233 | Novartis PharmaceuticalsINDUSTRY | 21 | Sep 17, 2026 | clinicaltrials |
| NCT07246564 | Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis | recruiting | Phase 4 | 40 | UCB Biopharma SRLINDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06285370 | A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy | completed | Phase 4 | 23 | Kyowa Kirin China Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07279935 | Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resectable SIB-IIIA NSCLC.(REVIVE) | recruiting | Phase 4 | 100 | AstraZenecaINDUSTRY | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07776821 | An Exploratory Study on the Efficacy and Safety of Enlonstobart Combined With Concurrent Radiotherapy and Chemotherapy Following Induction Therapy With Enlonstobart Plus Chemotherapy in Patients With Locally Advanced Cervical Cancer. | recruiting | Phase 4 | 31 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT02386800 | CINC424A2X01B Rollover Protocol | active not recruiting | Phase 4 | 279 | Novartis PharmaceuticalsINDUSTRY | 25 | Aug 20, 2026 | clinicaltrials |
| NCT01742299 | Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator | completed | Phase 4 | 155 | Novartis PharmaceuticalsINDUSTRY | 11 | Aug 18, 2026 | clinicaltrials |
| NCT07169331 | A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenström Macroglobulinemia | active not recruiting | Phase 4 | 16 | BeiGeneINDUSTRY | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07754812 | Oral Paclitaxel Solution With Immunotherapy and Concurrent SBRT as Neoadjuvant Treatment for Older Adults With NSCLC | recruiting | Phase 4 | 78 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07744698 | Metronomic Oral Paclitaxel Plus PD-1/ PD-L1 Inhibitor Maintenance in Advanced Lung Cancer (PULSE Study)(PULSE) | recruiting | Phase 4 | 107 | Anhui Provincial Cancer HospitalOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT04108208 | A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC) | completed | Phase 4 | 75 | Janssen Research & Development, LLCINDUSTRY | 1 | Jul 30, 2026 | clinicaltrials |
| NCT07709884 | A Single-center, Prospective, Single-arm Clinical Study Exploring the Treatment of Newly Diagnosed Multiple Myeloma Patients With t(11;14) Suitable for Transplantation Using the SonKRd Regimen | not yet recruiting | Phase 4 | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT07712328 | Randomized Controlled Clinical Study on the Prophylactic Intraoperative Use of Desmopressin in Complex Sellar Region Tumors(RCT-PIDST) | enrolling by invitation | Phase 4 | 152 | Zhaoyun ZhangOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT07600164 | Real-world Study of Pyrotinib-containing Regimens of Advanced HER2-positive Breast Cancer | recruiting | Phase 4 | 500 | Peking University People's HospitalOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07695259 | Olaparib+Trastuzumab+Pertuzumab Neoadjuvant for Elderly HER2+ Breast Cancer | recruiting | Phase 4 | 45 | Wen-Ming CaoOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT04877522 | Asciminib Roll-over Study | recruiting | Phase 4 | 347 | Novartis PharmaceuticalsINDUSTRY | 29 | Jul 6, 2026 | clinicaltrials |
| NCT05606315 | RemImazolam Besylate for ICU-sedation in Patients With Mechanical Ventilation After Oral and Maxillofacial Surgery | terminated | Phase 4 | 117 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT06057402 | Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)(MagnetisMM15) | recruiting | Phase 4 | 80 | PfizerINDUSTRY | 7 | Jul 1, 2026 | clinicaltrials |
| NCT07674368 | Rucaparib Monoclonal Antibody for Lorlatinib-Induced Hypercholesterolemia / Mixed | not yet recruiting | Phase 4 | 29 | Hunan Cancer HospitalOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07677566 | 177Lu-PSMA-617 Combined With Darolutamide in Neoadjuvant Treatment of High-risk Localized Prostate Cancer: a Prospective, Single-arm, Multi-center Clinical Trial(IUNU-PC-123) | not yet recruiting | Phase 4 | 20 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07665177 | Abrupt Discontinuation Versus Gradual Tapering of Propranolol in Infantile Hemangioma(PROIHSTOP) | not yet recruiting | Phase 4 | 110 | West China HospitalOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT07209787 | SIS-Reinforced vs. Conventional Anastomosis for Mid-to-Low Rectal Cancer: A Multicenter RCT on Anastomotic Leak | recruiting | Phase 4 | 966 | Beijing Chao Yang HospitalOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT07281677 | Immunogenicity and Safety of Sequential 2vHPV-9vHPV Vaccination in Girls Aged 9-14 Years | active not recruiting | Phase 4 | 400 | Zhejiang Provincial Center for Disease Control and PreventionOTHER_GOV | 1 | Jun 11, 2026 | clinicaltrials |
| NCT06437288 | Hematoporphyrin Photodynamic Therapy for Esophageal Cancer | enrolling by invitation | Phase 4 | 198 | Sun Yat-sen UniversityOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07150624 | The Treatment of Liver Injury After Liver Resection With Polyene Phosphatidylcholine | recruiting | Phase 4 | 96 | Anhui Provincial HospitalOTHER_GOV | 1 | May 11, 2026 | clinicaltrials |
| NCT07561892 | Study of the Effectiveness and Safety of Daunorubicin /Idarubicin ± Silibinin in Treating Newly Diagnosed AML (Non-M3).(AML) | recruiting | Phase 4 | 100 | Fujian Medical University Union HospitalOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT05457257 | Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations | active not recruiting | Phase 4 | 43 | AstraZenecaINDUSTRY | 1 | Apr 21, 2026 | clinicaltrials |
| NCT07091994 | A Trial of Edaravone Dexborneol in Acute Ischemic Stroke With Active Malignancy(PRECISE AM) | not yet recruiting | Phase 4 | 144 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT06282874 | Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases | active not recruiting | Phase 4 | 41 | Guangdong Association of Clinical TrialsOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT05160922 | Crizotinib Continuation Clinical Study | active not recruiting | Phase 4 | 27 | PfizerINDUSTRY | 5 | Mar 30, 2026 | clinicaltrials |
| NCT06423235 | Efficacy and Safety of Prunella Oral Liquid in the Treatment of Thyroid Nodules(ESPTTN) | recruiting | Phase 4 | 234 | Xintian PharmaceuticalINDUSTRY | 1 | Mar 24, 2026 | clinicaltrials |
| NCT07312370 | Esomeprazole Plus Sucralfate for Post-ESD Ulcer Healing | not yet recruiting | Phase 4 | 120 | LanZhou UniversityOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT07101588 | Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial | recruiting | Phase 4 | 200 | Chinese PLA General HospitalOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT07485920 | A Prospective, Multicenter Exploratory Clinical Study on Consolidation Therapy With Tislelizumab Combined With Nintedanib for Limited-stage Small Cell Lung Cancer | not yet recruiting | Phase 4 | 20 | The Affiliated Hospital of Qingdao UniversityOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT04726501 | CCCG-HD-2018 for Children and Adolescents With Newly Diagnosed Hodgkin Lymphoma | active not recruiting | Phase 4 | 200 | Children's Cancer Group, ChinaNETWORK | 1 | Mar 19, 2026 | clinicaltrials |
| NCT06013098 | Effects of Different Oxygen Concentrations on Pulmonary Complications in Patients Undergoing Radical Resection of Esophageal Cancer(DOICA-E) | completed | Phase 4 | 65 | China Medical University, ChinaOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT07469488 | A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese Patients With EGFR-Mutated Advanced NSCLC Receiving Amivantamab-Based Regimens(AmiCARE) | not yet recruiting | Phase 4 | 122 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT07445022 | RWS of Tunlametinib in NRAS-Mutant Advanced Melanoma | recruiting | Phase 4 | 110 | Fudan UniversityOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07446465 | FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectable pMMR/MSS Colorectal Cancer | not yet recruiting | Phase 4 | 42 | Ye XuOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07395596 | Remimazolam for Bronchoscopy in High-Risk Patients | recruiting | Phase 4 | 360 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Feb 24, 2026 | clinicaltrials |
Data updated 4 days agoSource updated unknownsource: clinicaltrials